Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(Ž) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.

Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR, BEGINŽ Basal-Bolus Type 1 trial investigators

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.

Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A, Johansen T, Ratner R, NN1250-3724 (BEGIN:EASY AM) and NN1250-3718 (BEGIN:EASY PM) Trial Investigators

Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.

Bray GA, Smith SR, Banerji MA, Tripathy D, Clement SC, Buchanan TA, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner RE, Schwenke DC, Stentz FB, Reaven PD, DeFronzo RA

Kynurenines and vitamin B6: link between diabetes and depression.

Oxenkrug G, Ratner R, Summergrad P

Scientific statement: Socioecological determinants of prediabetes and type 2 diabetes.

Hill JO, Galloway JM, Goley A, Marrero DG, Minners R, Montgomery B, Peterson GE, Ratner RE, Sanchez E, Aroda VR

Confirming glycemic status in the Diabetes Prevention Program: implications for diagnosing diabetes in high risk adults.

Christophi CA, Resnick HE, Ratner RE, Temprosa M, Fowler S, Knowler WC, Shamoon H, Barrett-Connor E, Kahn SE, Diabetes Prevention Program Research Group

The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.

Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner R, Balena R, T-emerge 2 Study Group

Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetes.

Aroda VR, Conway BN, Fernandez SJ, Matter NI, Maynard JD, Orchard TJ, Ratner RE

Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.

Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, Bray GA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Tripathy D, DeFronzo RA, Reaven PD

Insulin degludec improves health-related quality of life (SF-36ÂŽ ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.

Freemantle N, Meneghini L, Christensen T, Wolden ML, Jendle J, Ratner R

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.

Ratner RE, Gough SC, Mathieu C, Del Prato S, Bode B, Mersebach H, Endahl L, Zinman B

Effectiveness and cost-effectiveness of diabetes prevention among adherent participants.

Herman WH, Edelstein SL, Ratner RE, Montez MG, Ackermann RT, Orchard TJ, Foulkes MA, Zhang P, Saudek CD, Brown MB, Diabetes Prevention Program Research Group

Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study.

Diabetes Prevention Program Outcomes Study Research Group, Orchard TJ, Temprosa M, Barrett-Connor E, Fowler SE, Goldberg RB, Mather KJ, Marcovina SM, Montez M, Ratner RE, Saudek CD, Sherif H, Watson KE

[Food quality and nutritional status in university students of eleven Chilean regions].

Ratner RG, HernĂĄndez PJ, Martel JA, Atalah ES

The imperative to prevent diabetes.

Ratner RE